Long‐term survival of a patient with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) and untreated multiple brain metastases treated with zorifertinib: A case report

Abstract Brain metastases (BM) are common in patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) and confer poor prognoses. Zorifertinib (AZD3759), an EGFR‐tyrosine kinase inhibitor (TKI) with high blood‐brain barrier penetration, has previously demonstrat...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Kang Li, Bolin Chen, Jingyi Wang, Lin Wu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-06-01
Rangatū:	Thoracic Cancer
Ngā marau:	brain metastases EGFR‐mutant NSCLC third‐generation EGFR‐TKI zorifertinib
Urunga tuihono:	https://doi.org/10.1111/1759-7714.15317
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!